India’s largest pharmaceutical company, Ranbaxy Laboratories, is in the news again for an unsuccessful legal battle against American pharma giant, Pfizer in the US Court of Appeals. And the bone of contention remains the blockbuster drug Lipitor. Ranbaxy continues to challenge the Pfizer patent in many countries, in an attempt to launch its generic version as soon as possible. Th is has been the traditional economics of the Indian pharma industry. Lacking the resources and the right kind of support, Indian firms have largely depended on generics.
For complete IIPM article click here
Source:- IIPM Editorial
Visit also:- IIPM Publication, Business & Economy & Arindam Chaudhuri Initiative
For complete IIPM article click here
Source:- IIPM Editorial
Visit also:- IIPM Publication, Business & Economy & Arindam Chaudhuri Initiative
